Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 12, 2014 - Issue 1
Submit an article Journal homepage
6,713
Views
88
CrossRef citations to date
0
Altmetric
Editorial

New strategies against Stenotrophomonas maltophilia: a serious worldwide intrinsically drug-resistant opportunistic pathogen

Joanna S BrookeDepartment of Biological Sciences, College of Science and Health, DePaul University, Chicago, IL 60614, USACorrespondence[email protected]
Pages 1-4 | Published online: 04 Dec 2013

References

  • Looney WJ, Narita M, Mühlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect. Dis. 9(5), 312–323 (2009).
  • Liu Y-M, Chen Y-S, Toh H-S et al. In vitro susceptibilities of non-Enterobacteriaceae isolates from patients with intra-abdominal infections in the Asia-Pacific region from 2003 to 2010: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Int. J. Antimicrob. Agents 40(S1), S11–S17 (2012).
  • Gales AC, Castanheira M, Jones RN, Sader HS. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008–2010). Diagn. Microbiol. Infect. Dis. 73(4), 354–360 (2012).
  • Falagas ME, Kastoris AC, Vouloumanou EK, Dimopoulos G. Community-acquired Stenotrophomonas maltophilia infections: a systematic review. Eur. J. Clin. Microbiol. Infect. Dis. 28(7), 719–730 (2009).
  • Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin. Microbiol. Rev. 25(1), 2–41 (2012).
  • Pompilio A, Crocetta V, Confalone P et al. Adhesion to and biofilm formation on IB3-1 bronchial cells by Stenotrophomonas maltophilia isolates from cystic fibrosis patients. BMC Microbiol. 10, 102 (2010).
  • Brooke JS, Vo A, Watts P, Davis NA. Mutation of a lipopolysaccharide synthesis gene results in increased biofilm of Stenotrophomonas maltophilia on plastic and glass surfaces. Ann. Microbiol. 58(1), 35–40 (2008).
  • Waters VJ, Gomez MI, Soong G, Amin S, Ernst R, Prince A. Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia. Infect. Immun. 75(4),1698–1703 (2007).
  • Di Bonaventura G, Pompilio A, Zappacosta R et al. Role of excessive inflammatory response to Stenotrophomonas maltophilia lung infection in DBA/2 mice and implications for cystic fibrosis. Infect. Immun. 78(6), 2466–2476 (2010).
  • Waters V, Yau Y, Prasad S et al. Stenotrophomonas maltophilia in cystic fibrosis. Serologic response and effect on lung disease. Am. J. Resp. Crit. Care Med. 183, 635–640 (2011).
  • Sanchez MB, Hernández A, Martínez JL. Stenotrophomonas maltophilia drug resistance. Future Microbiol. 4(6), 655–660 (2009).
  • Abbott IJ, Slavin MA, Thursky KA, Turnidge JD, Worth LJ. Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment. Expert Rev. Anti Infect. Ther. 9(4), 471–488 (2011).
  • Berg G, Eberl L, Hartmann A. The rhizosphere as a reservoir for opportunistic human pathogenic bacteria. Environ. Microbiol. 7(11), 1673–1685 (2005).
  • Martínez JL. Antibiotics and antibiotic resistance genes in natural environments. Science 321(5887), 365–367 (2008).
  • Gülmez D, Çakar A, Şener B, Karakaya J, Hasçelik G. Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing. J. Infect. Chemother. 16(5), 322–328 (2010).
  • Milne KEN, Gould IM. Combination antimicrobial susceptibility testing of multidrug-resistant Stenotrophomonas maltophilia from cystic fibrosis patients. Antimicrob. Agents Chemother. 56(8), 4071–4077 (2012).
  • Goldberg E, Bishara J. Contemporary unconventional clinical use of co-trimoxazole. Clin. Microbiol. Infect. 18(1), 8–17 (2012).
  • Parkins MD, Elborn JS. Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management. J. Antimicrob. Chemother. 65(9), 1853–1861 (2010).
  • Farrell DJ, Sader HS, Jones RN. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob. Agents Chemother. 54(6), 2735–2737 (2010).
  • Geller DE, Flume PA, Griffith DC et al. Pharmacokinetics and safety of MP-376 (Levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob. Agents Chemother. 55(6), 2636–2640 (2011).
  • Wu K, Yau YCW, Matukas L, Waters V. Biofilm compared to conventional antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from cystic fibrosis patients. Antimicrob. Agents Chemother. 57(3), 1546–1548 (2013).
  • Parra-Riffo H, Lemus-Peñaloza J. Severe levofloxacin-induced hypoglycemia: a case report and literature review. Nefrologia 32(4), 546–547(2012).
  • Gould VC, Okazaki A, Avison MB. Coordinate hyperproduction of SmeZ and SmeJK efflux pumps extends drug resistance in Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 57(1), 655–657 (2013).
  • Ryan RP, Fouhy Y, Fernandez Garcia B et al. Interspecies signalling via the Stenotrophomonas maltophilia diffusible signal factor influences biofilm formation and polymyxin tolerance in Pseudomonas aeruginosa. Mol. Microbiol. 68(1), 75–86 (2008).
  • Fournier P-E, Drancourt M, Colson P, Rolain J-M, La Scola B, Raoult D. Modern clinical microbiology: new challenges and solutions. Nature Rev. Microbiol. 11(8), 574–585 (2013).
  • Ji Y, Lei T. Antisense RNA regulation and application in the development of novel antibiotics to combat multidrug resistant bacteria. Science Prog. 96(1), 43–60 (2013).
  • Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of phage therapy. Future Microbiol. 8(6), 769–783 (2013).
  • LiPuma JJ, Rathinavelu S, Foster BK et al. In vitro activities of a novel nanoemulsion against Burkholderia and other multidrug-resistant cystic fibrosis-associated bacterial species. Antimicrob. Agents Chemother. 53(1), 249–255 (2009).
  • Pieren M, Tigges M. Adjuvant strategies for potentiation of antibiotics to overcome antimicrobial resistance. Curr. Opin. Pharmacol. 12(5), 551–555 (2012).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.